MetSense Pilot and Feasibility

Part of paid clinical trials in Pleasanton, California.

Sponsor
Kaiser Permanente
Study ID
NCT07264062
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MetSense Risk Flag — BEHAVIORAL
    The MetSense risk flag alerts the clinician if the patient has high diabetes risk and prompts additional diabetes risk management.
  • Usual Care — OTHER
    Participants will receive usual care.

Study Details

People with serious mental illness have high risk for type 2 diabetes due to multiple risk factors, including the metabolic side effects of psychotropic medications that are used to treat these conditions. Type 2 diabetes is preventable through lifestyle and pharmacological interventions, but many people with serious mental illness do not receive regular screening for type 2 diabetes risk. In many health care settings, clinical pharmacists are increasingly managing patients with serious mental illness and have expertise in monitoring the metabolic side effects of psychotropic medications. This study evaluates the feasibility and acceptability of using a diabetes prediction model that is based on electronic health record data (the MetSense risk flag) to alert clinical pharmacists about patients who are at high diabetes risk, prompting these clinicians to prioritize diabetes risk management services.

Key Dates

Start date
Dec 1, 2025
Status verified
Feb 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: MetSense
    Participants will be managed by clinical pharmacists who are able to view the MetSense risk flag.
  • Other: Usual Care
    Participants will receive usual care. They will be managed by clinical pharmacists who are not able to view the MetSense risk flag.

Primary Outcome Measure

Percent with completed hemoglobin A1c test within 6 months. [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
KPNC Division of ResearchPleasantonCalifornia94588-

Find similar trials in Pleasanton, CA

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
KPNC Division of Research· Pleasanton, CA

Related Studies